SARS-CoV-2 infection in the heart transplant recipient
Review of the literature and reported case series has not reported an increased risk of SARS-CoV-2 infection in heart transplant recipients. However, this population is at increased risk of a more severe infection with increased mortality because of age and the presence of multiple comorbid conditions There is no significant difference in presenting symptoms in transplant recipients as compared to nontransplant patients, although diarrhea has been reported to be more frequent in transplant patients, a common side effect of immunosuppressive medications. Standard preventive measures have been shown to be equally protective in heart transplant recipients. Risk factors for severe disease and mortality are similar in both transplant recipients and nontransplant patients and include older age and the presence of comorbidities hypertension being the most common. The SARS-CoV-2 infection did not increase the risk of transplant allograft rejection. Currently, there are no specific treatment recommendations for SARS-CoV-2 infection in transplant recipients. However, the International Society of Heart and Lung and Transplant has issued guidance on how to modulate immunosuppressive therapy during SARS-CoV-2 infection..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Heart Views - 21(2020), 3, Seite 220-224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jassim Zaheen Shah [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Covid-19 |
|---|
| doi: |
10.4103/HEARTVIEWS.HEARTVIEWS_155_20 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ066280451 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ066280451 | ||
| 003 | DE-627 | ||
| 005 | 20230309055737.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/HEARTVIEWS.HEARTVIEWS_155_20 |2 doi | |
| 035 | |a (DE-627)DOAJ066280451 | ||
| 035 | |a (DE-599)DOAJ8dc6da750973423aa57de884881ee5d3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC666-701 | |
| 100 | 0 | |a Jassim Zaheen Shah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 infection in the heart transplant recipient |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Review of the literature and reported case series has not reported an increased risk of SARS-CoV-2 infection in heart transplant recipients. However, this population is at increased risk of a more severe infection with increased mortality because of age and the presence of multiple comorbid conditions There is no significant difference in presenting symptoms in transplant recipients as compared to nontransplant patients, although diarrhea has been reported to be more frequent in transplant patients, a common side effect of immunosuppressive medications. Standard preventive measures have been shown to be equally protective in heart transplant recipients. Risk factors for severe disease and mortality are similar in both transplant recipients and nontransplant patients and include older age and the presence of comorbidities hypertension being the most common. The SARS-CoV-2 infection did not increase the risk of transplant allograft rejection. Currently, there are no specific treatment recommendations for SARS-CoV-2 infection in transplant recipients. However, the International Society of Heart and Lung and Transplant has issued guidance on how to modulate immunosuppressive therapy during SARS-CoV-2 infection. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a heart transplant | |
| 650 | 4 | |a immunosuppressive therapy | |
| 650 | 4 | |a sars-cov-2 | |
| 653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
| 700 | 0 | |a Salah Elbdri |e verfasserin |4 aut | |
| 700 | 0 | |a Ashfaq Ahmad Patel |e verfasserin |4 aut | |
| 700 | 0 | |a Amr Mohamed Hamed Badr |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Heart Views |d Wolters Kluwer Medknow Publications, 2018 |g 21(2020), 3, Seite 220-224 |w (DE-627)DOAJ000103993 |x 09765123 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:3 |g pages:220-224 |
| 856 | 4 | 0 | |u https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_155_20 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/8dc6da750973423aa57de884881ee5d3 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.heartviews.org/article.asp?issn=1995-705X;year=2020;volume=21;issue=3;spage=220;epage=224;aulast=Shah |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1995-705X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 3 |h 220-224 | ||